A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 182 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 5 that started in 2013, is one of 9 in phase 3, and was the 11th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Second Xiangya Hospital of Central South University · Sites in China
Ages 18+
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 12 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,398 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 32 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 32 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 2nd largest by enrollment of the 149 interventional ones that give a count, is one of 14 that started in 2013, is one of 54 in phase 3, and was the 154th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 1,398 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: liraglutide
Drug: liraglutide
Drug: placebo
Drug: placebo
Drug: placebo
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).
Time frame: Week 0, week 52
Change From Baseline in Body Weight
Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.
Time frame: Week 0, week 52
Change From Baseline in Total Daily Insulin Dose
Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.
Time frame: Week 0, week 52
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes
This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of \<3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.
Time frame: Weeks 0-52
The trial was conducted at 177 sites in 17 countries: Argentina: 6, Australia: 5, Belgium: 4, Canada: 14, Germany: 8, Finland: 6, France: 13, United Kingdom: 10, Ireland: 5, Israel: 6, Netherlands: 6, Norway: 5, Poland: 5, Russia: 5, Sweden: 4, Ukraine: 5, United States: 70
| Milestone | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| Started | 351 | 350 | 349 | 348 |
| Exposed | 350 | 348 | 347 | 348 |
| Completed | 300 | 265 | 258 | 274 |
| Not completed | 51 | 85 | 91 | 74 |
| Withdrew: Adverse event | 15 | 41 | 49 | 14 |
| Withdrew: Protocol violation | 6 | 3 | 2 | 4 |
| Withdrew: Met withdrawal criteria | 13 | 13 | 21 | 27 |
| Withdrew: Unclassified | 17 | 28 | 19 | 29 |
Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).
| percentage of glycosylated haemoglobin | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | -0.45 ± 0.741 | -0.50 ± 0.767 | -0.54 ± 0.729 | -0.34 ± 0.707 |
Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.
| kg | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -1.34 ± 4.183 | -2.73 ± 4.524 | -4.02 ± 4.873 | 0.94 ± 3.828 |
Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.
| ratio | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Total Daily Insulin Dose | 1.04 ± 23.75 | 0.98 ± 26.66 | 0.95 ± 24.21 | 1.04 ± 26.69 |
This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of \<3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.
| episodes | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes | 4954 | 4602 | 4614 | 3654 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 0.6 mg | — | 35/350 (10%) | 259/350 (74%) |
| Liraglutide 1.2 mg | — | 36/348 (10.3%) | 263/348 (75.6%) |
| Liraglutide 1.8 mg | — | 29/347 (8.4%) | 282/347 (81.3%) |
| Placebo | — | 38/348 (10.9%) | 224/348 (64.4%) |
| Event | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/350 | 7/348 | 5/347 | 13/348 |
| Hypoglycaemic unconsciousnessNervous system disorders | 5/350 | 3/348 | 6/347 | 6/348 |
| Urinary tract infectionInfections and infestations | 0/350 | 0/348 | 3/347 | 0/348 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 3/350 | 1/348 | 3/347 | 0/348 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/350 | 3/348 | 3/347 | 2/348 |
| AppendicitisInfections and infestations | 0/350 | 1/348 | 0/347 | 2/348 |
| Macular oedemaEye disorders | 0/350 | 0/348 | 1/347 | 0/348 |
| DysphagiaGastrointestinal disorders | 0/350 | 0/348 | 1/347 | 0/348 |
| AbscessInfections and infestations | 0/350 | 0/348 | 1/347 | 0/348 |
| Abscess limbInfections and infestations | 0/350 | 0/348 | 1/347 | 0/348 |
| Event | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 112/350 | 141/348 | 172/347 | 42/348 |
| NasopharyngitisInfections and infestations | 105/350 | 81/348 | 83/347 | 85/348 |
| DiarrhoeaGastrointestinal disorders | 41/350 | 50/348 | 64/347 | 38/348 |
| VomitingGastrointestinal disorders | 24/350 | 44/348 | 64/347 | 21/348 |
| Decreased appetiteMetabolism and nutrition disorders | 31/350 | 43/348 | 64/347 | 6/348 |
| HeadacheNervous system disorders | 56/350 | 46/348 | 49/347 | 40/348 |
| Upper respiratory tract infectionInfections and infestations | 33/350 | 23/348 | 43/347 | 40/348 |
| DyspepsiaGastrointestinal disorders | 26/350 | 27/348 | 38/347 | 8/348 |
| Abdominal painGastrointestinal disorders | 20/350 | 16/348 | 29/347 | 8/348 |
| GastroenteritisInfections and infestations | 21/350 | 15/348 | 29/347 | 15/348 |
Full analysis set (FAS) included all randomised subjects who received at least one dose and had any post-randomisation data. Five subjects, who started the study, were excluded because of no exposure to study drug and 4 subjects were excluded because of non-availability of post-baseline data.
| Age, Continuous(years) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 43.6 ± 12.78 | 43.9 ± 13.06 | 43.7 ± 13.33 | 43.4 ± 12.57 | 43.7 ± 12.93 |
| Gender(Participants) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 186 | 179 | 181 | 180 | 726 |
| Male | 164 | 167 | 165 | 167 | 663 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.18 ± 0.738 | 8.16 ± 0.779 | 8.14 ± 0.740 | 8.15 ± 0.728 | 8.16 ± 0.746 |
| Body weight(kg) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 86.54 ± 17.338 | 85.39 ± 17.210 | 86.27 ± 17.321 | 86.41 ± 17.768 | 86.15 ± 17.397 |
| Total daily actual insulin dose-continuous subcutaneous insulin infusion(units) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Geometric mean | 52.97 (13.8 to 137.1) | 50.73 (19.7 to 160.5) | 50.46 (8.7 to 150.2) | 49.18 (3.9 to 176.1) | 50.65 (3.9 to 176.1) |
| Total daily actual insulin dose - Multiple daily injections(units) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Placebo | Total |
|---|---|---|---|---|---|
| Geometric mean | 59.54 (22.9 to 181.6) | 59.61 (16 to 282.5) | 62.52 (16.4 to 271.3) | 62.42 (20.3 to 230) | 60.94 (16 to 282.5) |
Showing the first 100 of 182 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2013, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide